Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model

Molecular Genetics and Metabolism

Volumn 106, Issue 1, 2012, Pages 83-91

  Macedo, Maria Fatima ^a,b,c   Quinta, Rui ^a,d   Pereira, Catia Sofia ^a   Sa Miranda, Maria Clara ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b INSTITUTO PIAGET   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

Enzyme replacement therapy; Fabry disease; INKT; Lysosomal storage diseases

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; LEUKOCYTE; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; THYMOCYTE;

ALPHA-GALACTOSIDASE; ANIMALS; CD4 LYMPHOCYTE COUNT; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; LIVER; LYSOSOMES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; SPLEEN; TRIHEXOSYLCERAMIDES;

ANIMALIA; MUS;

EID: 84860197221     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.02.014     Document Type: Article

References (53)

1. Desnick R.J., Blieden L.C., Sharp H.L., Hofschire P.J., Moller J.H. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976, 54:818-825.
2. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2812-2817.
3. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 2001, 38:750-760.
4. Ries M., Moore D.F., Robinson C.J., Tifft C.J., Rosenbaum K.N., Brady R.O., Schiffmann R., Krasnewich D. Quantitative dysmorphology assessment in Fabry disease. Genet. Med. 2006, 8:96-101.
5. Schiffmann R. Fabry disease. Pharmacol. Ther. 2009, 122:65-77.
6. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
7. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2004, 75:65-74.
8. Thurberg B.L., Rennke H., Colvin R.B., Dikman S., Gordon R.E., Collins A.B., Desnick R.J., O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002, 62:1933-1946.
9. Thurberg B.L., Fallon J.T., Mitchell R., Aretz T., Gordon R.E., O'Callaghan M.W. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009, 119:2561-2567.
10. Lidove O., West M.L., Pintos-Morell G., Reisin R., Nicholls K., Figuera L.E., Parini R., Carvalho L.R., Kampmann C., Pastores G.M., Mehta A. Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet. Med. 2010, 12:668-679.
11. Weidemann F., Linhart A., Monserrat L., Strotmann J. Cardiac challenges in patients with Fabry disease. Int. J. Cardiol. 2010, 141:3-10.
12. Warnock D.G., Ortiz A., Mauer M., Linthorst G.E., Oliveira J.P., Serra A.L., Marodi L., Mignani R., Vujkovac B., Beitner-Johnson D., Lemay R., Cole J.A., Svarstad E., Waldek S., Germain D.P., Wanner C. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol. Dial. Transplant. 2011, 0:1-8.
13. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., Sugimoto Y., Pastan I., Gottesman M.M., Brady R.O., Kulkarni A.B. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2540-2544.
14. Ohshima T., Schiffmann R., Murray G.J., Kopp J., Quirk J.M., Stahl S., Chan C.C., Zerfas P., Tao-Cheng J.H., Ward J.M., Brady R.O., Kulkarni A.B. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6423-6427.
15. Rodrigues L.G., Ferraz M.J., Rodrigues D., Pais-Vieira M., Lima D., Brady R.O., Sousa M.M., Sa-Miranda M.C. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol. Dis. 2009, 33:48-56.
16. Rozenfeld P.A., Fritz M., Blanco P., Gonzalez P., Rinaldi G.J. Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy. Can. J. Cardiol. 2011, 27:339-345.
17. Valbuena C., Oliveira J.P., Carneiro F., Relvas S., Ganhao M., Sa-Miranda M.C., Rodrigues L.G. Kidney histologic alterations in alpha-galactosidase-deficient mice. Virchows Arch 2011, 458:477-486.
18. Ioannou Y.A., Zeidner K.M., Gordon R.E., Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 2001, 68:14-25.
19. Lee K., Jin X., Zhang K., Copertino L., Andrews L., Baker-Malcolm J., Geagan L., Qiu H., Seiger K., Barngrover D., McPherson J.M., Edmunds T. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003, 13:305-313.
20. Sakuraba H., Chiba Y., Kotani M., Kawashima I., Ohsawa M., Tajima Y., Takaoka Y., Jigami Y., Takahashi H., Hirai Y., Shimada T., Hashimoto Y., Ishii K., Kobayashi T., Watabe K., Fukushige T., Kanzaki T. Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery. J. Hum. Genet. 2006, 51:341-352.
21. Sakuraba H., Murata-Ohsawa M., Kawashima I., Tajima Y., Kotani M., Ohshima T., Chiba Y., Takashiba M., Jigami Y., Fukushige T., Kanzaki T., Itoh K. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J. Hum. Genet. 2006, 51:180-188.
22. Murray G.J., Anver M.R., Kennedy M.A., Quirk J.M., Schiffmann R. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol. Genet. Metab. 2007, 90:307-312.
23. Marshall J., Ashe K.M., Bangari D., McEachern K., Chuang W.L., Pacheco J., Copeland D.P., Desnick R.J., Shayman J.A., Scheule R.K., Cheng S.H. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 2010, 5:e15033.
24. Togawa T., Kawashima I., Kodama T., Tsukimura T., Suzuki T., Fukushige T., Kanekura T., Sakuraba H. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem. Biophys. Res. Commun. 2010, 399:716-720.
25. Choi J.O., Lee M.H., Park H.Y., Jung S.C. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer. J. Biomed. Sci. 2010, 17:26.
26. Saris J.J., Derkx F.H., Lamers J.M., Saxena P.R., Schalekamp M.A., Danser A.H. Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-phosphate receptors. Hypertension 2001, 37:710-715.
27. Weber M.M., Kiess W., Beikler T., Simmler P., Reichel M., Adelmann B., Kessler U., Engelhardt D. Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II/mannose-6-phosphate (IGF-II/M6P) receptors in bovine adrenal cells. Eur. J. Endocrinol. 1994, 130:265-270.
28. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
29. Dao T., Guo D., Ploss A., Stolzer A., Saylor C., Boursalian T.E., Im J.S., Sant'Angelo D.B. Development of CD1d-restricted NKT cells in the mouse thymus. Eur. J. Immunol. 2004, 34:3542-3552.
30. Egawa T., Eberl G., Taniuchi I., Benlagha K., Geissmann F., Hennighausen L., Bendelac A., Littman D.R. Genetic evidence supporting selection of the Valpha14 iNKT cell lineage from double-positive thymocyte precursors. Immunity 2005, 22:705-716.
31. Benlagha K., Wei D.G., Veiga J., Teyton L., Bendelac A. Characterization of the early stages of thymic NKT cell development. J. Exp. Med. 2005, 202:485-492.
32. Berzins S.P., Smyth M.J., Baxter A.G. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol. 2011, 11:131-142.
33. Wu L., Gabriel C.L., Parekh V.V., Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 2009, 73:535-545.
34. Gadola S.D., Silk J.D., Jeans A., Illarionov P.A., Salio M., Besra G.S., Dwek R., Butters T.D., Platt F.M., Cerundolo V. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J. Exp. Med. 2006, 203:2293-2303.
35. Darmoise A., Teneberg S., Bouzonville L., Brady R.O., Beck M., Kaufmann S.H., Winau F. Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010, 33:216-228.
36. Balreira A., Macedo M.F., Girao C., Rodrigues L.G., Oliveira J.P., Sa Miranda M.C., Arosa F.A. Anomalies in conventional T and invariant natural killer T-cell populations in Fabry mice but not in Fabry patients. Br. J. Haematol. 2008, 143:601-604.
37. Prigozy T.I., Naidenko O., Qasba P., Elewaut D., Brossay L., Khurana A., Natori T., Koezuka Y., Kulkarni A., Kronenberg M. Glycolipid antigen processing for presentation by CD1d molecules. Science 2001, 291:664-667.
38. Plati T., Visigalli I., Capotondo A., Buono M., Naldini L., Cosma M.P., Biffi A. Development and maturation of invariant NKT cells in the presence of lysosomal engulfment. Eur. J. Immunol. 2009, 39:2748-2754.
39. Schumann J., Facciotti F., Panza L., Michieletti M., Compostella F., Collmann A., Mori L., De Libero G. Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism. Eur. J. Immunol. 2007, 37:1431-1441.
40. Zhou D., Mattner J., Cantu C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306:1786-1789.
41. Sagiv Y., Hudspeth K., Mattner J., Schrantz N., Stern R.K., Zhou D., Savage P.B., Teyton L., Bendelac A. Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein. J. Immunol. 2006, 177:26-30.
42. Schrantz N., Sagiv Y., Liu Y., Savage P.B., Bendelac A., Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J. Exp. Med. 2007, 204:841-852.
43. Rozenfeld P., Agriello E., De Francesco N., Martinez P., Fossati C. Leukocyte perturbation associated with Fabry disease. J. Inherit. Metab. Dis. 2009, 10.1007/s10545-009-1060-9.
44. Mills K., Johnson A., Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett. 2002, 515:171-176.
45. Goossens P.L., Jouin H., Marchal G., Milon G. Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver. J. Immunol. Methods 1990, 132:137-144.
46. Abe A., Gregory S., Lee L., Killen P.D., Brady R.O., Kulkarni A., Shayman J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 2000, 105:1563-1571.
47. Pintos-Morell G., Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur. J. Pediatr. 2009, 168:1355-1363.
48. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002, 195:625-636.
49. Takahashi T., Chiba S., Nieda M., Azuma T., Ishihara S., Shibata Y., Juji T., Hirai H. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 2002, 168:3140-3144.
50. Lee P.T., Benlagha K., Teyton L., Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 2002, 195:637-641.
51. Schmieg J., Yang G., Franck R.W., Van Rooijen N., Tsuji M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1127-1132.
52. Geissmann F., Cameron T.O., Sidobre S., Manlongat N., Kronenberg M., Briskin M.J., Dustin M.L., Littman D.R. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005, 3:e113.
53. Bricard G., Porcelli S.A. Antigen presentation by CD1 molecules and the generation of lipid-specific T cell immunity. Cell. Mol. Life Sci. 2007, 64:1824-1840.